Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Neurochemistry International

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neuint.2015.12.004PMID 26743617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson's disease.

  2016cited by this paper
• Endoplasmic reticulum and lysosomal Ca2+ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts

  2016cited by this paper
• Viable Neuronopathic Gaucher Disease Model in Medaka (Oryzias latipes) Displays Axonal Accumulation of Alpha-Synuclein

  2016cited by this paper
• Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada

  2016influential reference
• The association between alterations of eye movement control and cerebral intrinsic functional connectivity in Parkinson’s disease

  2016cited by this paper
• Progressive decline of glucocerebrosidase in aging and Parkinson's disease

  2015cited by this paper
• Plasma Oligomeric Alpha‐Synuclein Is Associated With Glucocerebrosidase Activity in Gaucher Disease

  2015cited by this paper
• Peripheral ß-glucocerebrosidase enzyme activity and lipidomics in ß-glucocerebrosidase (GBA1) mutation Parkinson disease (P2.149)

  2015cited by this paper
• Emerging therapeutic targets for Gaucher disease

  2015influential reference
• Enzyme replacement and substrate reduction therapy for Gaucher disease.

  2015influential reference
• Consanguinity and founder effect for Gaucher disease mutation G377S in a population from Tabuleiro do Norte, Northeastern Brazil

  2015cited by this paper
• Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.

  2015cited by this paper
• Differential effects of severe vs mild GBA mutations on Parkinson disease

  2015influential reference
• Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology

  2015cited by this paper
• Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains.

  2015cited by this paper
• Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.

  2015cited by this paper
• Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

  2015influential reference
• Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease.

  2015cited by this paper
• Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model.

  2015cited by this paper
• Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.

  2015cited by this paper
• Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies

  2015cited by this paper
• Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson’s Disease

  2015cited by this paper
• Repression of rRNA transcription by PARIS contributes to Parkinson's disease.

  2015cited by this paper
• Color Discrimination in Patients with Gaucher Disease and Parkinson Disease

  2015cited by this paper
• Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice.

  2015cited by this paper
• Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease

  2015influential reference
• Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C.

  2015cited by this paper
• Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death

  2015cited by this paper
• Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation

  2015cited by this paper
• Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.

  2015cited by this paper
• No evidence for substrate accumulation in Parkinson brains with GBA mutations

  2015cited by this paper
• Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation

  2015cited by this paper
• Activation of p38 Mitogen-Activated Protein Kinase in Gaucher’s Disease

  2015cited by this paper
• The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease

  2015influential reference
• Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease

  2015cited by this paper
• Spectrum of GBA mutations in patients with Gaucher disease from Slovakia: identification of five novel mutations.

  2015cited by this paper
• Antisaccades and executive dysfunction in early drug‐naive Parkinson's disease: The discovery study

  2015cited by this paper
• Brain-derived neurotrophic factor expression increases after enzyme replacement therapy in Gaucher disease.

  2015cited by this paper
• Quality of life and Gaucher disease

  2015cited by this paper
• Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells.

  2015cited by this paper
• Viable Neuronopathic Gaucher Disease Model in Medaka (Oryzias latipes) Displays Axonal Accumulation of Alpha-Synuclein

  2015cited by this paper
• GBA‐associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study

  2015cited by this paper
• Variants associated with Gaucher disease in multiple system atrophy

  2015influential reference
• Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.

  2015influential reference
• Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease

  2015cited by this paper
• Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.

  2014influential reference
• Two novel mutations in glucocerebrosidase, C23W and IVS7-1 G>A, identified in Type 1 Gaucher patients heterozygous for N370S.

  2014cited by this paper
• Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.

  2014influential reference
• Visual short-term memory deficits associated with GBA mutation and Parkinson’s disease

  2014cited by this paper
• Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

  2014influential reference
• Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model.

  2014cited by this paper
• Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients.

  2014cited by this paper
• Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells

  2014cited by this paper
• Significant study of population stratification, sensitivity analysis and trim and fill analyses on GBA mutation and parkinson's disease

  2014cited by this paper
• LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance

  2014cited by this paper
• Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease.

  2014influential reference
• A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy

  2014cited by this paper
• RIPK3 as a potential therapeutic target for Gaucher's disease

  2014cited by this paper
• Glucocerebrosidase mutations in primary parkinsonism

  2014influential reference
• MiRNAs and glucocerebrosidase: lessons from miRNA mimic screening

  2014cited by this paper
• Immunotherapy Targeting Tau and Amyloid Aβ Pathology in AD Animal Models

  2014cited by this paper
• Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein

  2014cited by this paper
• The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease

  2014cited by this paper
• Gaucher disease: a diagnostic challenge for internists.

  2014cited by this paper
• Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.

  2014cited by this paper
• Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease

  2014cited by this paper
• Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes.

  2014influential reference
• ATP13A2/PARK9 Regulates Secretion of Exosomes and α-Synuclein

  2014cited by this paper
• Identification of novel mutations in glucocerebrosidase (GBA) gene in Indian patients with gaucher disease (GD)

  2014cited by this paper
• PS Dependent APP Cleavage Regulates Glucosylceramide Synthase and is Affected in Alzheimer's Disease

  2014cited by this paper
• Lysosome sorting of β-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor

  2014cited by this paper
• Abnormal pupillary light reflex with chromatic pupillometry in Gaucher disease

  2014cited by this paper
• Structural Features of Membrane-bound Glucocerebrosidase and α-Synuclein Probed by Neutron Reflectometry and Fluorescence Spectroscopy*

  2014cited by this paper
• iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease.

  2014cited by this paper
• Lysosomal integral membrane protein 2 (LIMP-2) restricts the invasion of Trypanosoma cruzi extracellular amastigotes through the activity of the lysosomal enzyme β-glucocerebrosidase.

  2014cited by this paper
• Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation.

  2014cited by this paper
• Alpha-synuclein and tau: teammates in neurodegeneration?

  2014influential reference
• Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.

  2014cited by this paper
• Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease.

  2014cited by this paper
• The LIMP-2/SCARB2 Binding Motif on Acid β-Glucosidase

  2014cited by this paper
• Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice.

  2014cited by this paper
• Glucocerebrosidase mutations in Thai patients with Parkinson's disease.

  2014influential reference
• Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS

  2014cited by this paper
• ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.

  2014cited by this paper
• Management of Gaucher disease: enzyme replacement therapy.

  2014cited by this paper
• Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease

  2014cited by this paper
• Macrophage Models of Gaucher Disease for Evaluating Disease Pathogenesis and Candidate Drugs

  2014influential reference
• Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.

  2014influential reference
• Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson’s disease

  2014influential reference
• Eliglustat: First Global Approval

  2014cited by this paper
• Novel heterozygous c.798C>G and c.1040T>G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1

  2014cited by this paper
• Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

  2014influential reference
• iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis

  2014influential reference
• Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis

  2013cited by this paper
• The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease

  2013cited by this paper
• Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

  2013cited by this paper
• Retinal Nerve Fiber Layer Thinning in Dementia Associated with Parkinson's Disease, Dementia with Lewy Bodies, and Alzheimer's Disease

  2013cited by this paper
• Glucocerebrosidase mutations in a Serbian Parkinson's disease population

  2013influential reference
• The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia

  2013cited by this paper
• Is Parkinson disease associated with lysosomal integral membrane protein type-2?: challenges in interpreting association data.

  2013cited by this paper

• A PheWAS approach to identify associations of GBA1 variants with comprehensive phenotypes beyond neurological diseases

  2025cites this paper
• Multitask Deep Learning for Predicting Parkinson’s Progression and Depression From Multimodal Time Series Data

  2025cites this paper
• Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypes

  2025cites this paper
• Executive dysfunction in Parkinson's disease: From neurochemistry to circuits, genetics and neuroimaging.

  2025cites this paper
• Data-driven characterization of distinct cognitive subtypes in Parkinson’s disease dementia

  2025cites this paper
• Mass spectrometry‐based proteomics for biomarker discovery in the Drosophila model of Parkinson's disease

  2024cites this paper
• Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease.

  2024cites this paper
• Prediction of Parkinson's disease pathogenic variants using hybrid Machine learning systems and radiomic features.

  2023cites this paper
• Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson’s disease

  2023cites this paper
• ReviewEmerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A

  2022cites this paper
• What to Test in Parkinson Disease Prevention Trials?

  2022cites this paper
• Epigallocatechin gallate for Parkinson's disease

  2022cites this paper
• Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update

  2022cites this paper
• Bioengineered models of Parkinson’s disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment

  2022cites this paper
• Synaptic Function and Dysfunction in Lysosomal Storage Diseases

  2021cites this paper
• Induced pluripotent stem cell derived from postmortem tissue in neurodegenerative disease research

  2021cites this paper
• Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinson’s disease

  2021cites this paper
• GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson’s Disease

  2021cites this paper
• Association of gender and age at onset with glucocerebrosidase associated Parkinson’s disease: a systematic review and meta-analysis

  2021cites this paper
• Advancing Personalized Medicine in Common Forms of Parkinson’s Disease through Genetics: Current Therapeutics and the Future of Individualized Management

  2021cites this paper
• Identification of GBA mutations among Neurodegenerative disease Patients from eastern India.

  2021cites this paper
• Mitophagy, a Form of Selective Autophagy, Plays an Essential Role in Mitochondrial Dynamics of Parkinson’s Disease

  2021cites this paper
• Characterization of a pathogenic variant in GBA for Parkinson’s disease with mild cognitive impairment patients

  2020cites this paper
• Effects of glucocerebrosidase gene polymorphisms and mutations on the risk of Parkinson's disease dementia: a meta-analysis.

  2020cites this paper
• Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease

  2020cites this paper
• The contribution of CNVs to the most common aging-related neurodegenerative diseases

  2020cites this paper
• Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses

  2020cites this paper
• Neuropathophysiology of Lysosomal Storage Diseases: Synaptic Dysfunction as a Starting Point for Disease Progression

  2020cites this paper
• Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells

  2020cites this paper
• Glucocerebrosidase genetic variants in Malays with early and late-onset Parkinson’s disease

  2020cites this paper
• Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies

  2020cites this paper
• Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism

  2020cites this paper
• Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson’s disease and dementia: review and meta-analyses. Running title: Review of GBA and neuropsychiatric phenotypes Authors:

  2020cites this paper
• The Emerging Role of the Lysosome in Parkinson’s Disease

  2020cites this paper
• Common GBA Variants in Parkinson's Disease and Lewy Body Dementia Patients

  2020cites this paper
• The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease

  2020cites this paper
• GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches

  2019cites this paper
• Effects of progesterone at the enteric level in a mouse model of Parkinson's disease

  2019cites this paper
• Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease.

  2019cites this paper
• Immune system and new avenues in Parkinson’s disease research and treatment

  2019cites this paper
• Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.

  2019cites this paper
• Silencing of Glucocerebrosidase Gene in Drosophila Enhances the Aggregation of Parkinson's Disease Associated α-Synuclein Mutant A53T and Affects Locomotor Activity

  2018cites this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cites this paper
• Treatable inherited rare movement disorders

  2018cites this paper
• Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinson’s Disease

  2018cites this paper
• Parkinson's disease: Cause factors, measurable indicators, and early diagnosis

  2018cites this paper
• Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta‐analyses

  2018cites this paper
• Impact of ethnicity on the natural history of Parkinson disease

  2018cites this paper
• Molecular regulations and therapeutic targets of Gaucher disease.

  2018cites this paper
• Modeling Parkinson’s Disease in Drosophila: What Have We Learned for Dominant Traits?

  2018cites this paper
• Association of variants in microRNA with Parkinson’s disease in Chinese Han population

  2018cites this paper
• Connecting Gaucher and Parkinson Disease: Considerations for Clinical and Research Genetic Counseling Settings

  2017cites this paper
• Genetic and perinatal risk factors for movement disorders

  2017cites this paper
• A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments

  2017cites this paper
• GBA mutations in Parkinson disease: earlier death but similar neuropathological features

  2017cites this paper
• Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters

  2016cites this paper
• The biomarkers of immune dysregulation and inflammation response in Parkinson disease

  2016cites this paper
• Lipid pro�les in the cerebrospinal �uid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson's disease

  year unknowncites this paper
• Impact of ethnicity on the natural history of Parkinson disease

  year unknowncites this paper